Introduction
Cardiovascular disease is the leading cause of death in dialysis patients and sudden death (SD) represents a significant proportion of overall mortality in both hemodialysis (HD) and peritoneal dialysis (PD) patients. SD accounts for about 37 .0% of all causes of death in patients with end stage renal disease (ESRD) and for 65.0% of cardiovascular deaths. The rate of cardiac arrest is 7.3% in HD and 6.0% in PD patients [1] . There is evidence showing that left ventricular ejection fraction (LVEF) is the best predictor of total and sudden mortality in patients with cardiac disease, but without ESRD [2] [3] [4] . The factors associated with SD in patients undergoing dialysis are not very clear. It was shown that the high incidence of SD in HD patients could be partly explained by the rapid changes of plasma electrolytes related to the intermittent nature of this dialysis technique [5, 6] . However, in PD patients, factors that can cause SD, despite continuous treatment,
are not yet clear and few studies were carried out on this topic. Moreover, there are no data comparing the incidence of SD in HD patients with those undergoing PD.
In the last few years, several studies comparing the risk of total mortality in HD patients and patients on PD were performed. Almost all these studies showed a better survival during the first period from the start of dialysis in PD than in HD patients, but it is unclear whether the dialysis modality is associated with greater long-term survival [7] [8] [9] [10] [11] [12] .
The purpose of the present study is to assess, in a population of ESRD patients, the relationship between the different dialysis modality (HD vs. PD) and overall and sudden mortality and to identify predictors of outcomes for each dialysis modality.
Methods
In this Italian multicenter retrospective study, all dialysis patients (undergoing HD or PD) referred to 7 dialysis centers of Lombardy, alive on the January 1, 2010, or starting dialysis between January 1, 2010, and January 31, 2013 (recruitment time), were enrolled and their clinical charts were revised. Patients were considered eligible for the study only if an echocardiogram with a measured value of LVEF was available, either obtained within 6 months before recruitment if alive, or 6 months before death if deceased. Information on the presence of the following comorbidities was collected: ischemic cardiac disease, diabetes mellitus, previous stroke, and atrial fibrillation. Death causes were derived from medical records. The presence of an implanted cardioverter defibrillator (ICD) was also considered. SD was defined as spontaneous death preceded by a sudden loss of consciousness within 1 h after onset of acute symptoms, even in the presence of pre-existing heart disease, but with unexpected timing and mode. Nephrologists or relatives were interviewed to confirm all cases of SD. Procedures were performed according to the Helsinki declaration for ethics treatment of human subjects and approved by the local Ethical Committee.
Statistical Analysis
Study end points were the following: a. Overall survival defined as the time from the start of dialysis to the time of death from any cause; b. Cause of death; c. Cause-specific survival defined as the time from the start of dialysis to the time of SD or other cause. Survival data of patients starting dialysis before the January 1, 2010, and alive on the January 1, 2010, were left-truncated [13] . In other terms, these patients were not considered at risk of death during the interval time between the beginning of dialysis and January 1, 2010 (i.e., truncation period).
Overall survival distribution was estimated by the product-limit method. A linear time by treatment interaction term was introduced in a Cox regression model to demonstrate formally the curvature over time of the relative hazard function. The average hazard of death per unit time (i.e., each year following dialysis start) was estimated. A fixed-effects meta-regression was fitted to the point and standard error estimate of the average hazard of death per unit time. A meta-regression forest plot was used to summarize meta-regression results. The Cox regression model was used to evaluate predictors of overall survival and test their interaction with treatment.
In order to estimate the statistical association between the 2 cohorts of patients (i.e., HD and PD patients) and the specific cause of death (i.e., SD) and to identify patient characteristics statistically associated to the specific cause of death, a survival analysis in the presence of competing risks was performed. The Fine and Gray regression model was used to estimate the cause-specific hazards ratio (HR cpRisk ).
In the Cox multivariable and Fine and Gray regression models, ICD implantation was considered a time-varying treatment.
Survival status was updated on the January 31, 2014. Median follow-up and its interquartile range (IQR) were estimated with the reverse Kaplan-Meier method [14] . The completeness index (C) [15] was used in order to quantify the completeness of followup at the update of survival status.
Baseline covariate distributions were summarized using descriptive statistics (median and range for continuous variables, and absolute and percentage frequencies for categorical variables). The logistic regression model was used to detect imbalances between baseline covariate distributions.
Statistical analysis was performed using Figure 1 shows the survival curves of the 2 populations; at the start of dialysis, the survival of PD patients was higher than that of HD patients (HR [ Fig. 2 a) . Because the likelihood The analysis relative to the influence of each comorbidity on total mortality in the 2 cohorts of patients is shown in Table 3 . In both populations, factors associated with an increased risk of mortality were older age, LVEF ≤ 35%, and the presence of ischemic heart disease, diabetes mellitus, previous strokes, and atrial fibrillation. The HR for individual comorbidity was higher in patients on PD, and the interaction test for dialysis treatment (HD vs. PD) was significant for ischemic heart disease ( p value <0.001), diabetes mellitus ( p value = 0.02), and atrial fibrillation ( p value = 0.01).
Multivariable analysis confirmed that PD patients had a lower risk of death than HD patients (HR 0.13, 95% CI 0.05-0.33, p value <0.001) at the start of dialysis, and that the difference was significantly reduced with increasing time (HR [linear interaction with time] 1.33, 95% CI 1.20-1.46, p value <0.001). The independent association between risk of death and older age, ischemic heart disease, LVEF ≤ 35%, diabetes mellitus, previous stroke, and atrial fibrillation was also confirmed. An interaction effect between dialysis modality and comorbidities was still present for ischemic heart disease ( p value = 0.01) and atrial fibrillation ( p value = 0.03; Table 4 ).
Sudden Death
During follow-up, 84 SDs occurred. SD, excluding unknown causes, accounted for 22.8% (13 of 57) of causes of death in PD patients and 12.1% (71 of 588) in those on HD. There was no significant difference in the incidence of SD among patients on HD compared to PD patients, although the latter showed an increased risk of 23.0% (HR cpRisk 1.23, 95% CI 0.68-2.23, p value = 0.49; Fig. 3 ). The time from starting dialysis treatment did not significantly affect the HR cpRisk and the incidence of SD in either group ( p value [linear interaction with time] = 0.19; Fig. 2 b) . Time since dialysis start, years Among HD patients who died suddenly, 58 of 71 (81.7%) had an LVEF >35%, while among PD patients who suffered a SD, those with preserved LVEF were 7 of 13 (53.8%; p value = 0.03). A total of 22 of 48 (45.8%) HD patients, in whom the timing of death with respect to the HD session could be established, died during the first inter-dialytic interval and 18 of 48 (37.5%) during the last long inter-dialytic interval of the week.
The analysis of the influence of each comorbidity on SD risk in the 2 cohorts of patients is shown in Table 5 . Variables associated with a higher incidence of SD in HD patients were older age, presence of LVEF ≤ 35%, ischemic heart disease, and diabetes mellitus, while in patients on PD, reduced LVEF, previous strokes, and slightly ischemic heart disease were associated with SD. The interaction test for dialysis treatment (HD versus PD) was not significant for any of the comorbidities considered.
Multivariable analysis showed that factors significantly associated with SD were older age, presence of LVEF ≤ 35%, ischemic heart disease, and also diabetes mellitus. The difference in SD incidence was not significantly influenced by dialysis modality (HR cpRisk 1.24, 95% CI 0.68-2.26, p value = 0.49; Table 6 ).
Discussion
This study shows that, in an ESRD population, survival is higher in PD than in HD patients. SD incidence, however, is not different in the 2 cohorts of patients and SD, when considering all causes of death, is relatively more frequent in PD than in HD patients.
In the literature, data on mortality risk comparing PD with HD are not univocal [11, 12, [16] [17] [18] [19] . It is likely that patients reaching ESRD due to acute renal failure or hav- ing worse clinical conditions are preferentially placed on HD. The frailty of these patients may increase early mortality after starting renal replacement therapy [20] ; however, in our study, the survival of PD patients still remains higher compared to HD patients, even after eliminating early mortality from the analysis. Nevertheless, this advantage decreases over time from starting dialysis therapy. Moreover, in PD patients, the presence of each comorbidity determines an increase in the risk of death for any cause by 2-3 times compared to HD patients, and this finding is particularly evident for ischemic heart disease and atrial fibrillation. This result confirms what had already been observed by other authors [19, 21] . In ESRD patients, the presence of diabetes mellitus and poor glycemic control are often associated with several clinical complications and with an increase of mortality, particularly in PD patients [22] [23] [24] . In addition, in the tissues of PD patients, diabetic or not, there is a great deposition of advanced glycation end products that predispose to the metabolic syndrome [25] , a condition associated with an increased risk of cardiovascular mortality in this population [26] . Several studies demonstrated that, in PD patients, accelerated atherosclerosis processes are actively present and suggest that atherosclerosis risk is even higher in PD than in HD patients [27] [28] [29] . An increased risk of death in HD patients with atrial fibrillation has been described [30] , while there are no data on atrial fibrillation and mortality in PD patients. The HD session may trigger episodes of atrial fibrillation, particularly of the paroxysmal type [31, 32] . It is possible that, in our study population, PD patients had more frequent forms of permanent atrial fibrillation and that this may partly justify the higher risk of death associated with the arrhythmia compared to HD patients. Non-paroxysmal atrial fibrillation, in fact, is usually associated with the presence of cardiac disease and with a highly significant increase in thromboembolism and death [33] . Moreover, HD patients meet their nephrologist 3 times a week, while PD patients perform only monthly clinical checks. This could create a less effective clinical monitoring of cardiovascular disease in the latter population.
In our population, the incidence of SD was independent of dialysis modality and even slightly higher in subjects undergoing PD. Data also show that, among all causes of death, SD was about twice as frequent in PD as in HD patients. The reported SD incidence is 49 per 1,000 patients per year in the HD population and 36 per 1,000 patients per year in the population on PD [1] . The factors that lead PD patients to die suddenly could somewhat differ from those that induce SD in HD patients. A previous study linked SD in PD patients with reduced LVEF and elevated plasma levels of pro-BNP and troponin T, suggesting an important role of heart failure and ischemic heart disease as factors associated with increased sudden mortality [34] . In our population, among patients who suffered SD, prevalence of subjects with LVEF ≤ 35% was higher in PD compared to HD patients. This finding suggests that the presence of severe cardiac disease could play an important role in determining SD in the PD population, while in HD patients factors that are most closely related to dialysis modality may be relevant. In an Australian population, a daily variation in the pattern of cardiac deaths was observed in HD patients receiving 3 dialysis sessions per week, but not in PD patients [35] . SD occurs more frequently during the long inter-dialytic interval or after the first HD session of the week [5, 6] , and in 50 HD patients having an implanted cardiac monitor, the risk of SD and significant arrhythmias was greatest during the long inter-dialytic interval [36] . Moreover, HD sessions themselves can cause cardiac arrest and lower concentrations of potassium and calcium in the dialysate are associated with a higher incidence of cardiac intradialytic arrest [37, 38] . In agreement with these data, we observed that the majority of SDs of our HD patients occurred just before or just after the first HD session of the week. All this evidence partly justifies the high SD incidence in HD patients, even in those with preserved LVEF, but it is not clear as to why sudden mortality is also high in PD patients. The effects of intra-dialytic modifications of the electrolytes on the cardiac action potential have been widely investigated in HD patients [39] [40] [41] , while very few studies have been done regarding possible electrolyte disturbances in PD patients and their potential arrhythmogenic effects. However, both HD and PD populations show an alteration of potassium handling, even if the electrolyte plasma fluctuations differ in relation to different dialysis modalities. Some authors have shown an excess of mortality in PD patients associated with serum potassium disturbances. Torlén et al. [42] described that PD patients are more likely to have serum potassium <4 mEq/L compared to HD patients and that there is a Ushaped relationship between time-averaged serum potassium and PD patients' mortality. Recently, it was reported that both time-averaged serum potassium and its fluctuation contribute to the high death risk in PD patients [43] . These studies allow us to hypothesize that electrolyte abnormalities could increase the risk of death also in this population. Our study has some limitations being a retrospective study. A treatment selection bias was present, because the nephrologist was free to choose the dialysis modality for each patient. Moreover, data on plasma concentrations of electrolytes in the 2 study populations are lacking. However, our data show that SD is an important clinical problem even in the PD population and not only in HD patients and strongly suggest the need to undertake studies with the aim of understanding the mechanisms behind this type of death in patients undergoing PD.
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